FOR IMMEDIATE DISTRIBUTION
SBH Sciences and Cell Assay Innovations
Announce an Agreement to Provide Kinase Cell-based Screening Services
(Beverly, MA) April 30, 2012. Cell Assay Innovations (CAI), a biotechnology company dedicated to developing innovative cell-based assays for drug discovery, announced today that it has entered into an agreement with SBH Sciences of Natick, MA, to provide kinase cellular screening services. "We're very excited about working with SBH Sciences," commented Dr. Deborah Moshinsky, PhD, President of CAI. "Their extensive expertise in the area of cell-based assays for cytokines is a great complement for our kinase cell-based assay platform." Dr. Raphael Nir, PhD, President of SBH Sciences, added, "We're happy to have the opportunity to introduce this unique kinase cell-based assay service to accompany our multiple services for compound testing in cytokine and other cellular assays."
Under the terms of the agreement, CAI will provide the assay technology, and SBH Sciences will perform compound screening services. Assay offerings will include popular tyrosine and serine/threonine kinase targets involved in Oncology, Inflammation, and other disease areas. Compound testing services will be available for each assay as they are introduced, with the goal of a panel of 10 assays within 6 months. Assays are currently available for lck, EphB4, Pim2, and FGFR1.
About Cell Assay Innovations
CAI is a privately owned biotechnology company founded in 2011, located in Beverly, MA. Its mission is to develop innovative assay platforms for cell-based drug discovery. The CAI management team has extensive experience in drug discovery and compound testing, having worked in various biotechnology and large pharmaceutical companies. In addition to developing novel cell-based assays, CAI also performs routine cytotoxicity and apoptosis assays for oncology, including combination studies. For more information, visit www.cellassayinnov.com
About SBH Sciences
Founded in 1997, SBH Sciences is an innovative preclinical contract research organization (CRO) focused on anti-cancer and anti-inflammation drug development. In its 15 years of working with over 100 biotechnology and diagnostic companies, SBH Sciences has earned a reputation for product quality, excellent service, and on-time delivery. They also partner with early-stage biotechnology companies to provide incubator-model support, as well as cell-based discovery, cytokine and enzyme production, and immunological and analytical services. Notably, their collection of 280+ cytokine bioassays is the most comprehensive in the US. SBH Sciences is also very active in cytotoxicity testing, biomarker measurement, and functional activity testing. For more information, visit www.sbhsciences.com